ArticleFrontiers in endocrinology2026
Overexpression of FGFR1 in AgRP neurons protects against obesity and improves glucose homeostasis.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Background: The rising prevalence of metabolic disorders highlights the need to identify targetable pathways. Although hypothalamic AgRP neuron signaling influences energy balance, the beneficial role of fibroblast growth factor receptor 1 (FGFR1) within these neurons remains incompletely understood. Methods: We employed an AAV-mediated CRISPR/Cas9 activation system to achieve AgRP neuron-specific overexpression of FGFR1 in adult mice. Metabolic phenotypes were assessed during high-fat diet (HFD) feeding, and mechanistic insights were gained using GT1-7 hypothalamic cells. Results: FGFR1 overexpression in AgRP neurons attenuated high-fat diet (HFD)-induced weight gain and improved glucose tolerance, effects that were associated with reduced energy intake. Mechanistically, FGFR1 overexpression correlated with increased FOXO1 phosphorylation and reduced AgRP mRNA expression, suggesting a potential FGFR1-FOXO1 regulatory axis. Conclusion: These findings identify a contributory role for AgRP neuronal FGFR1 signaling in modulating metabolic outcomes under HFD conditions and suggest that this pathway may represent a potential avenue for further investigation in the context of obesity and diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.